Camlipixant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Camlipixant
- Molecular weight
- 458.47
- Structure (SMILES)
- CNC(=O)c1cc(F)c(-c2nc3cc(C)ccn3c2C[C@H]2CN(C(=O)OC)CCO2)c(F)c1
- az 13410937
- AZ-13410937
- az13410937
- AZ13410937
- blu 5937
- Blu-5937
- BLU-5937
- BLU-5937 ER
- BLU-5937 IR
- blu5937
- BLU5937
- camlipixant
- Camlipixant
- Camlipixant [INN]
- CAMLIPIXANT [USAN]
- Camlipixant [WHO-DD]
- camlipixant inn
- camlipixant usan
- camlipixant who dd
- neo 5937
- NEO-5937
- neo5937
- NEO5937
- CAS registry numbers
- 1621164-74-6
- ChEMBL ID
- CHEMBL5095035
- InChIKey
- SEHLMRJSQFAPCJ-HNNXBMFYSA-N
- PubChem compound IDs
- 76955630
- FDA ingredient codes (UNII)
- TB7D2H7MZZ
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- camlipixant
- Type
- Synthetic organic
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2X3
- Gene symbol
- P2RX3
- Protein identifier
- P56373
- Median affinity
- 7.6
- Affinity units
- pIC50
- Mechanism
- P2X purinoceptor 3 antagonist
- Action type
- Antagonist
- Target
- P2X purinoceptor 3
- Protein identifier
- P56373
- Action
- Non-competitive
- Action type
- NON_COMPETITIVE
- Target
- P2X3
- Gene symbol
- P2RX3
- Protein identifier
- P56373
- Median affinity
- 7.6
- Affinity units
- pIC50
Open Targets mechanisms
- Mechanism
- P2X purinoceptor 3 antagonist
- Action type
- Antagonist
- Target
- P2X purinoceptor 3
- Condition
- Pruritus
- Highest recorded phase
- 1
- Condition identifier
- HP:0000989
- Subject identifier
- D011537
- Condition
- Chronic Cough
- Highest recorded phase
- 1
- Condition identifier
- HP:0012735
- Subject identifier
- D000096822
- Condition
- Cough
- Highest recorded phase
- 2
- Condition identifier
- HP:0012735
- Subject identifier
- D003371
- Condition identifier
- HP_0000989
- Condition identifier
- HP_0000989
- Highest recorded phase
- 2
- Condition identifier
- HP_0012735
- Condition identifier
- HP_0012735
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- NCT03638180
- NCT03979638
- NCT05570539
- NCT06222892
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 85.17
- Calculated partition coefficient (ALogP)
- 2.96
- Calculated partition coefficient (XLogP)
- 3.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 33
- Molecular formula
- C23H24F2N4O4
- Monoisotopic mass
- 458.17656158
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (16)
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
- A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
- A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
- A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
- A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
- A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
- A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
- Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
- BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
- Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
- Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
- Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
- Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
Targets (1)
- P2RX3 P2X purinoceptor 3 antagonist